Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Sticks to Its Buy Rating for Natera (NTRA)

Tipranks - Tipranks - Thu Apr 16, 4:06AM CDT

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Natera, with a price target of $280.00.

Claim 30% Off TipRanks

Sergott covers the Healthcare sector, focusing on stocks such as Qiagen, Pacific Biosciences, and Agilent. According to TipRanks, Sergott has an average return of -3.6% and a 36.43% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $257.27 average price target.

See the top stocks recommended by analysts >>

Based on Natera’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $665.5 million and a net profit of $47.26 million. In comparison, last year the company earned a revenue of $476.06 million and had a GAAP net loss of $53.77 million

Read More on NTRA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).